Gastrointestinal Cancer
News from the FDA/CDC
Liver cancer death rates down for Asians and Pacific Islanders
Long-term decrease bucks the larger trend of rising rates.
Conference Coverage
No survival boost with atezolizumab vs. regorafenib in mCRC
BARCELONA – There was no overall or progression-free survival benefit from the PD-L1 inhibitor with or without cobimetinib vs. regorafenib alone...
From the Journals
Occult blood in feces linked to more than just colorectal cancer mortality
Positive fecal occult blood tests were associated with other disease-specific mortality outcomes, including circulatory, respiratory, and...
News
FDA grants accelerated approval to ipilimumab/nivolumab combo for CRC
The combo is approved for microsatellite instability-high or mismatch repair deficient metastatic CRC that has progressed.
News
Machine learning software boosts colonoscopists’ adenoma detection rates
Using more than 8,600 colonoscopy images researchers developed a software tool to aid colonoscopists in identifying adenomatous polyps.
From the Journals
Neuropilin-1 surpasses AFP as HCC diagnostic marker
Neuropilin-1 was a more sensitive and specific marker for HCC than alpha fetoprotein, the current standard.
Conference Coverage
Screen sooner and more often for those with family history of CRC
A family history of colorectal cancer is associated with risk of colorectal cancer, and screening guidelines should be adjusted accordingly.
Conference Coverage
Hints of nivolumab efficacy seen in biliary tract cancers
BARCELONA – Five patients with intrahepatic cholangiocarcinomas or gallbladder tumors had partial but durable responses in a phase 2 trial.
Conference Coverage
Trifluridine/tipiracil improves survival of metastatic gastric cancer
The oral thymidine analogue/thymidine phosphorylase inhibitor was associated with a 2.1 month overall survival benefit in heavily pretreated...
Conference Coverage
Pembrolizumab does not surpass paclitaxel for gastric cancer
BARCELONA – The immune checkpoint inhibitor was not statistically superior to paclitaxel, but trends point to better outcomes with pembrolizumab,...
Conference Coverage
Ramucirumab improves HCC survival after sorafenib failure
BARCELONA – A pooled analysis of two phase 3 trials showed a 3-month overall survival benefit in patients with alpha-fetoprotein levels of 400 ng/...